Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.09.17	Karolinska Development's portfolio company Umecrine Cognition presents positive phase 1b data for its drug candidate against hepatic encephalopathy (GlobeNewswire)
13.09.17	Karolinska Development's portfolio company BioArctic intends to list on Nasdaq Stockholm (GlobeNewswire)
05.09.17	Karolinska Development company Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors (GlobeNewswire)
31.08.17	Change of Number of Shares and Votes in Karolinska Development (GlobeNewswire)
29.08.17	Karolinska Development: Interim Report - January-June 2017 (GlobeNewswire)
29.08.17	Karolinska Development Appoints Fredrik Järrsten as Chief Financial Officer (GlobeNewswire)
25.08.17	Karolinska Development Notes the Planned Listing of Xspray AB on Nasdaq First North (GlobeNewswire)
24.08.17	Karolinska Development - Interim Report (January-June 2017) - Invitation to conference call and webcast (GlobeNewswire)
02.08.17	Karolinska Development company Aprea Therapeutics announces First Patient Enrolled in Phase Ib/II Clinical Study (GlobeNewswire)
24.02.17	UPDATE: Karolinska Development - Q4 and 2016 Year-End Report - clarifies publication time and new time for conference call and webcast (GlobeNewswire)
16.06.16	DGAP-News: Karolinska Development AB (B) (EQS Group)
06.06.16	DGAP-News: Karolinska Development AB (B) (EQS Group)
09.03.16	DGAP-News: Karolinska Development AB (B) (EQS Group)
10.10.13	Karolinska Development AB (publ): Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers (Businesswire)
27.08.13	Karolinska Development AB (publ): Lipidor reports positive clinical Phase I/II data in psoriasis (Businesswire)
22.08.13	Karolinska Development AB (publ): Purchase of own shares to cover social security fees related to incentive program (Businesswire)
01.08.13	Karolinska Development AB (publ): Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT (Businesswire)
04.07.13	Karolinska Development AB (publ): Pergamum Reports Positive Preliminary Efficacy Results from a Phase I/II Study of LL-37 in Patients with Chronic Leg Ulcers (Businesswire)
21.12.12	Karolinska Development AB (publ): Pergamum Reports Positive Phase II Data from Clinical Trial in Outer Ear Infections (Businesswire)
21.12.12	Karolinska Development AB (publ): Karolinska Development Announces a SEK 220 million Strategic Deal (Businesswire)
22.11.12	Karolinska Development AB (publ) - Interim Report January - September 2012 (Businesswire)
28.09.12	Karolinska Development AB (publ): Purchase of own shares to cover social security fees related to incentive program (Businesswire)
18.09.12	Karolinska Development AB (publ): Aprea Announces Positive Data from a Clinical Phase I/II Study with APR-246 in Patients with Advanced Cancers (Businesswire)
10.07.12	Karolinska Development AB (publ): Pergamum reports top line Phase II-data from the clinical trial for prevention of post-surgical adhesions (Businesswire)
13.06.12	Karolinska Development AB (publ): Karolinska Development arranges a share ownership exchange with Industrifonden (Businesswire)
12.06.12	Karolinska Development AB (publ): Pharmanest initiates Phase II study of SHACT (Businesswire)
24.05.12	Karolinska Development´s Annual General Meeting 2012 (Businesswire)
15.05.12	Karolinska Development AB (publ) - Interim report January - March 2012 (Businesswire)
30.04.12	Karolinska Development: Pharmanest initiates Phase I trial with SHACT (Businesswire)
19.04.12	Notice of Annual General Meeting of Karolinska Development AB (Publ) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten